drugset / Trial / NCT07094880

Subcuteous Methotrexate in Rheumatoid Arthritis

NCT07094880 ↗

Phase 4 Completed 45 enrolled Bangladesh Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

Methotrexate use is important for the treatment of Rheumatoid arthritis. Some patients can not tolerate oral methotrexate. So subcutaneous may help to overcome it.

Timeline

Start
2015-06-01
Primary completion
2016-06-01
Completion
2016-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methotrexate Small molecule 25 mg Oral

Indications